Pushing the boundary of cancer diagnostics through microfluidic technologies
-
-
REFERENCES
[1] Murphy, J.B., and Sturm, E. (1925). Primary lung tumors in mice following the cutaneous application of coal tar. J. Exp. Med. 42: 693−700. DOI: 10.1084/jem.42.5.693. [2] Nielsen, T.O., Parker, J.S., Leung, S., et al. (2010). A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer. Clin. Cancer Res. 16: 5222. DOI: 10.1158/1078-0432.CCR-10-1282. [3] Office of Science and Engineering Laboratories. (2021). Microfluidics program: Research on microfluidics-based medical devices. US Food and Drug Administration: https://www.fda.gov/medical-devices/medical-device-regulatory-science-research-programs-conducted-osel/microfluidics-program-research-microfluidics-based-medical-devices#:~:text=The%20Microfluidics%20Program%20focuses%20on. [4] Jonasson, O. (1958). The viability of circulating cancer cells in experimental cancer. Surg. Forum. 9: 577−580. [5] Kalluri, R., and McAndrews, K.M. (2023). The role of extracellular vesicles in cancer. Cell 186: 1610−1626. DOI: 10.1016/j.cell.2023.03.010. -
ABOUT THIS ARTICLE
Cite this article:
Wong AH. (2023). Pushing the boundary of cancer diagnostics through microfluidic technologies. The Innovation Medicine 1(1), 100005. https://doi.org/10.59717/j.xinn-med.2023.100005
Export File
Citation
Wong AH. (2023). Pushing the boundary of cancer diagnostics through microfluidic technologies. The Innovation Medicine 1(1), 100005. https://doi.org/10.59717/j.xinn-med.2023.100005
Format
Content
DownLoad:
-
Figure 1.
Examples of microfluidic technologies applied to (A) circulating tumor cell (CTC) isolation and (B) cell-based drug screening
Twitter